NCT07141329View on ClinicalTrials.gov

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Focal Onset Seizures
Interventions
DRUG

SPN-817

SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

Trial Locations (1)

33952

RECRUITING

Medsol Clinical Research Center, Port Charlotte

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT07141329 - SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | Biotech Hunter | Biotech Hunter